Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE (NCT06669754)
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Orally Administered Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of once-daily orally administered deucrictibant extended-release tablet compared to placebo for prophylaxis to prevent angioedema attacks in participants aged ≥ 12 years with hereditary angioedema.
Who can join: Review the eligibility criteria below.
Location: Study Site — Little Rock, Arkansas
Age range: 12 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (56 Sites)
Showing the first 25 of 56 sites.
- Study Site — Little Rock, Arkansas
- Study Site — San Diego, California
- Study site — Santa Monica, California
- Study site — Walnut Creek, California
- Study Site — Chevy Chase, Maryland
- Study Site — St Louis, Missouri
- Study Site — Corrientes,
- Study Site — San Martin,
- Study Site — Santo André,
- Study Site — Sofia,
- Study Site — Sofia,
- Study Site — Edmonton,
- Study Site — Ottawa,
- Study Site — Grenoble,
- Study Site — Lille,
- Study Site — Berlin,
- Study Site — Frankfurt,
- Study Site — Hanover,
- Study Site — Hong Kong,
- Study Site — Budapest,
- Study Site — Dublin,
- Study Site — Milan,
- Study Site — Padova,
- Study Site — Kawasaki,
- Study Site — Tokyo,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hereditary Angioedema (HAE)
- A Study of Navenibart in Participants With Hereditary Angioedema — Birmingham, Alabama
- A Phase 2 in Adult Subjects With Hereditary Angioedema — Silver Spring, Maryland
- Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE — Birmingham, Alabama
- Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients — Wheaton, Maryland
- Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE) — Litchfield Park, Arizona
Explore by condition: All Hereditary Angioedema (HAE) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.